Toll-like receptor による自己免疫・アレルギー制御

*47یnÅb;_^Ccs“
— ¦!)·É³ÊbZcAc+ÎÑ9˟% —
‡‹‚…‚…õw…Ý…ÍÐð
nÅS<@bvÝ¢ÕÍÐæ
òi ܛ
,1*
nÅÔ+ñà)‘u+d$,â/&2)™®È+x~')7Çxj+ko9ˆÌ
89¡
ö7'*7Toll-like receptorúTLRû,?aONBGa)(+Çxj*pë)±œœq9
ã癮ô“y–9äŠ7_JXKc&7éTLR ,Çxj)(+Ľ9ãç7"
&)»È)(*4#%Â7ی+œq*‰7–Ò*2óe%7'{8%7
5*یnÅƘ+ǚ* TLR +GEP^¹óe%7'2q#%%7«æº&
,یnÅb;_^Cc+ǚ*7 TLR '
+óîqƒ+µÚ9°å¦!)·É³ÊbZc
Ac+ÎÑ9˟!©é+Ìá*$%2ê.%0!
Û¼nÅ'À’nÅ
nÅÔ,g*]aTÁ¸è7À’nÅÔ'ZD`V:cH3´¿ÖÙ¸è7Û¼nÅÔ'*
‚q87À’nÅÔ, B ÖÙ5ÃÂ87nÅE`W]aú=jû3 T ÖÙz†j*4
6¾ÄÊ*Ľ9ãç7j+ñà)¾—,²)x*‰7²—9ª7+0&)
)?V>DKcµÚ*27nŖÒ*%©r*ÃÂ87j, IgM &7nŖ
Ò+ïß''2* IgG 3 IgAIgE D\I+jÃÂ87+µ±,D\II<ML×£'
|-8T ÖÙ5ÃÂ87 IL-4 3 IL-5 )(+F<NA<a3 CD40 )(*47Öـ¶GEP
^)(*4#%s“87
d§Û¼nÅÔ,UN3Z=I"&)]aTÁ9ž!)R?)(+¨Þ5*¯½)
(ŽÓ)Ï*l„8%7½+„*•÷+™®ô“µ±&7Û¼nÅÔ+‘u,™®ô
“+©tØ&ko!Çxj9ì3*ãç¡ö7'*7
+!1*j+4)¾Ä
Ê)Çxjãçµ±,ž!Çxj*pë+±í9ãç%Çxj9 ù¥¤¡ö7Û
¼nÅÔ*%Çxj+ãç*f”Ê)‘u9­!%7+TLR &7
Çxj+ãç*7 To ll- li ke r ec ep tor
TLR ,m¬R?+ Toll +}hø+Y[`E'%D`cQaE8!2+&7Toll ,R?*
3
ÁÐ/ÖØ,YCND]+Toll ¤—I5!Ñ"ÁЍŸ/å‰
%Toll TLR "'
È̀ám
Z3@[!Ê+Ý¡ß/”}!ÎÙÞ}D[J:
+£Í(¡ßëe,
*' TLR
,²Õ,TLR "`
%^¿ÈÌ(l¿ÈÌ
¥0
),ºrfÖØÄ/ÚãԍŸå‰£¡
R:ZL1]A¢®ÈÌ( B ÈÌ!j¸ÈÌ
'½±Ö&*-,
*TLR !½±"j¸ÈÌ
½±,
æ‚-
,."
TLR ÖØ,W7[H"TLR !Äë
))§%,h# TLR4 ";VT
ç‹Ð!¡m+˜Ò»!r|, LPSì5[HG8@[í/ÖØ,TLR2 ";VT
è‹Ð!WQPNEH/TLR9 "ÈÐ! CpG-DNA /ÖØ,b^!)ɞ"x TLR /¤
—R4BxW7[H
ƒktŠ
*m
,TLR
f!ÖØ"Æq"h# TLR4
, MD-2
),ºr
"À• LPS "ÉyTLR4 !È̀ám
LPS "À•Éy,. MD-2 " LPS Éy,‡o/TLR4 "ÈÌl
/d,‡o/)
cy
iw
‡om“,Ë*-,% TLR2 " TLR1 ( TLR6 cy
TLR
WQPNEH/ÖØ,Ë*-,!)
),·¬!ÖØ"TLR q¯"
ә!m
*,Ó飡,
Tol l -li ke recep tor
),2YX9]\τj¸n‰— â/ÖØ, TL R —
IgE "}2YX9]tŠ
–ÃÈÌ
ãÔj¸;ZMW[,2YX=[¢®ÈÌ!’r
u+Û%-2YX=[/ÖØ,OXJ]TìTh2íÈÌmp¦2YX=[
·‹!, B ÈÌ
IL-4 !?3G63[gµ,
­
) IgE ’f´³-,›Ü
!ÂÅ
*TLR9 W7[H, CpG-DNA ¢®ÈÌ%"À• B ÈÌ
gµIgE !´³/
‘n,š*
-" TLR /a,Ï«j¸Ç!iw°ˆj¸Ç/n‰,
/Ã,TLR !iw/n‰,2YX9]!¨¼
œµ,'Ã{
,
܆TLR €!·¬"ª»
m/ÖØ,Ã{-,TLR
,ºrf¶m!>[DS/…
)àê,K2XZ[â!τ!
),τ’r!ÖØ
ä"TLR !W7[H+
ˏ-#*>[DS"ך<]B
'~z-,ºrf! RNA ( DNA /ÖØ, TLR7 ( TLR9 τ! RNA ( DNA /ÖØ
,v͋,*
:VB!τ’f!´³
â!ÖØ
KG! SLE !UFXR4B/µÂÅ
*º¾ IgG2a IgG2b
"TLR9 !iwãÔ,Ã-,-*!
* ä., TLR τ! âm!ÖØs$τj¸¹Œ!ºŽ
{-,
4
©ä_,Ã
¡Hž€ttR(§©% TLR gMSl
RP105´CD180µ TLR4 Z B ˜› LPS §©=m–±'%Rd%#
TLR2 U¨˜¡9543.0§©
±'%#TLR7/9 $~®
˜¡¡Hž€ttR(§©% TLR 1)79>Rd%RP105 ˜›b­R MD-2 ²FRd% MD-1 EY%
RP105 ƒx6*-¢‡BM,;29< IgG3
IgG2a L
G@%#u RP105 vHŽ±A%š gvH"
‰“
rª&% gM‘o%±¬(¦SLE 8/:6*-´MRL/lpr-lpr 6*
-µ RP105 ƒx(fN%¯`6*-†«Ÿ¢—‰!…D‹y\
k#&
´^ 1µ™}#RP105 KW
HP¢—‰ap! SLE ’s±A
%
Cq&~®(§©% TLR ˜¡ž€ttR(§©% TLR
gtR(§©%Vœn
%(”[%
u RP105 EYRd% MD-1 „h6*-¢‡BVˆnŠse_%({
## SLE 8/:6*-„h6*-†«¢‡ MD-1 °
c6*-T
³OaT%(¤Q´^ 2µ
#T³ SLE 8/:6*-X•Ÿ] MD-1
mRNA ?z
§&Vˆn MD-1 ‰“=Mh“’sI#‚œ(w%
(i”$Œ_ MD-1 ƒx SLE 8/:6*-(J£B%MD-2 $
MD-1 LPS ™Y9+<0{#9+<0({#%‘o
’s%‚œ
¥{&%
|j&%
'$
5
TLR $'—‘¼¿Š†¨*ÂJa('Ê»uƒÌqŠ†'@~ TLR
šUI*¼¿'–
%›$“¶jvN*"¼¿—k$
&¶jL˜™t›®'"N% TLR —kË«;-93Qµ¢R
²ËÅ"¤[('OÄ TLR4 HWN` MD-2 ÐY´³É':;03=
É"­W'¤('$TLR ™tË)&§™t
%l&*!'TLR 8+:;?N`#ËÅN`›s™t>L˜—k›Œœˆž>
ŽQs9?.?&'*¯Ep"%\£ž¡ª5?1*·©P¸>Sœ
À’¯'
¾Ã
¡ª*ǹ'&odͽm*{zÏ'eh TYÈi…Ò„Ó
eh ¸
…ÅWHwg(' 11 ¥G…Ÿ‡Ò҄Ӌ”‰¬]
҄ÓnÁ]2,6҄Ó
4,.º
¸Ò„Ó
‚C¸Z҄ÓSi҄Óe^Rbi…Ò„Ó҄Óe^¸Z€Œ¸Z҄Ó҄Ó
ÎÆ];?7/:.<҄ÓÓu¾
qxfÏ
ª°'‚D_bS¦b¡ªwAcKF|y"u¾•B
э±r|yMX¡
V¯}’
1. Nagai, Y., Shimazu, R., Ogata, H., et al. Blood 2002; 99: 1699.
2. Nagai, Y., Akashi, S., Nagafuku, et al. Nat. Immunol. 2002; 3: 667.
3. Nagai, Y., Kobayashi, T., Motoi, Y., et al. J. Immunol. 2005; 174: 7043.
4. Kobayashi, T., Takahashi, K., Nagai Y., et al. Int. Immunol. 2008; 20: 881.
6
]
W
 p @Š ‹ '3)/
E-mail: [email protected]
[nŒ690303„'3q3cgŠ'3‹
^%qHlcgx< 5-"JG
3WŒ
:A 7 ; 3 O z'e03'3'3e (T
:A 10 ; 4 O z'e0303„'3kcge )/uf
3
Š^rY3ŒPQ…1JG‹
:A 14 ; 3 O , nWŒ
:A 7 ; 4 O z'e03'3ƒ8_„ !e c'
:A 8 ; 4 O zbh_„2\‡ !e c'
:A 9 ; 4 O ‰\†._„ !e 7'
:A 14 ; 4 O e3EsFoVU B]a%|cgI}T )/cg ŠR03'e3cgC ?S^‚ ?S~3#€ C8Œ
4JG‹
:A 16 ; 3 O Oklahoma Medical Research Foundation,
Immunobiology and Cancer Research Program,
Associate Research ScientistŠPaul W. Kincade )/‹
:A 17 ; 7 O , Senior Research Scientist M
:A 18 ; 3 O R03'e3cgC ?S^‚ ^vj#€ &D
ŠˆXm>JG‹
:A 19 ; 4 O 690303„'3q3cgŠ'3‹5-"JG
C83ŒLQ^3LQ!e3
cg#€Œ^3TLR _*tyVUZ`^$=VU
+{iŒ:A 14 ; z'e0303„'3kcgedwK{ŠNd{‹
7
14 Young Investigator’s Award
8